Skip to content

PD-1 Knockout Engineered T Cells for Advanced Colorectal Cancer with MSI high expression

A Phase II Trial of PD-1 Knockout Engineered T Cells for the Treatment of Advanced Colorectal Cancer with MSI high expression progressed after multi-line treatment

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IIh-17010392
Enrollment
Unknown
Registered
2017-01-11
Start date
2017-01-16
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Colorectal Cancer with MSI high expression

Interventions

Sponsors

Anhui Province Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Stage III/B or IV colorectal cancer with MSI high expression; 2. Measurable disease; 3. Progressed after all standard treatment; 4. ECOG performance status of 0-2; 5. Expected life span: >= 3 months; 6. Toxicities from prior treatment has resolved. Washout period is 4 weeks for chemotherapy, and 2 weeks for targeted therapy; 7. Major organs function normally; 8. Women at pregnant ages should be under contraception; 9. Hematologic studies satisfy the following requirements within 1 week before treatment: WBC=3×10^9/L; ANC=1.5×10^9/L; Hb=80g/L;

Exclusion criteria

Exclusion criteria: 1. Pathology is not colorectal cancer or without MSI high expression; 2. Emergent treatment of tumor emergency is needed; 3. Poor vasculature; 4. Coagulopathy, or ongoing thrombolytics and/or anticoagulation; 5. Blood-borne infectious disease, e.g. hepatitis B; 6. History of mandatory custody because of psychosis or other psychological disease inappropriate for treatment deemed by treating physician; 7. With other immune diseases, or chronic use of immunosuppressants or steroids; 8. Compliance cannot be expected; 9. Other conditions requiring exclusion deemed by physician.

Design outcomes

Primary

MeasureTime frame
Number of participants with Adverse Events and/or Dose Limiting Toxicities as a Measure of Safety and tolerability of dose of PD-1 Knockout T cells using Common Terminology Criteria for Adverse Events (CTCAE v4.0) in patients;

Secondary

MeasureTime frame
Response Rate;Progression free survival (PFS);Overall Survival (OS);Peripheral blood circulating tumor DNA;Temporal Interleukin-2 change in the peripheral blood;Temporal Interferon-? change in the peripheral blood;

Countries

China

Contacts

Public ContactYueyin Pan

Anhui Province Hospital

yueyinpan1965@163.com+86 13805695536

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026